Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Achieve control: a pragmatic clinical trial of insulin glargine 300 U/mL versus other basal insulins in insulin-naïve patients with type 2 diabetes.
Oster G, Sullivan SD, Dalal MR, Kazemi MR, Rojeski M, Wysham CH, Sung J, Johnstone B, Cali AM, Wei LJ, Traylor L, Anhalt H, Hull M, Van Vleet J, Meneghini LF. Oster G, et al. Among authors: cali am. Postgrad Med. 2016 Nov;128(8):731-739. doi: 10.1080/00325481.2016.1241663. Epub 2016 Oct 24. Postgrad Med. 2016. PMID: 27690710 Clinical Trial.
A pragmatic randomized clinical trial of insulin glargine 300 U/mL vs first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 6-month outcomes of the ACHIEVE Control study.
Meneghini LF, Sullivan SD, Oster G, Busch R, Cali AMG, Dauchy A, Gill J, Bailey TS. Meneghini LF, et al. Among authors: cali amg. Diabetes Obes Metab. 2020 Nov;22(11):2004-2012. doi: 10.1111/dom.14152. Epub 2020 Sep 3. Diabetes Obes Metab. 2020. PMID: 32729217 Free PMC article. Clinical Trial.
Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice-daily basal insulin to once-daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (EDITION 1 and EDITION 2 subgroup analysis).
Roussel R, d'Emden MC, Fisher M, Ampudia-Blasco FJ, Stella P, Bizet F, Cali AMG, Wysham CH. Roussel R, et al. Among authors: cali amg. Diabetes Obes Metab. 2018 Feb;20(2):448-452. doi: 10.1111/dom.13071. Epub 2017 Sep 14. Diabetes Obes Metab. 2018. PMID: 28736942 Free PMC article. Clinical Trial.
A post-hoc pooled analysis to evaluate the risk of hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus 100 U/mL (Gla-100) over wider nocturnal windows in individuals with type 2 diabetes on a basal-only insulin regimen.
Bolli GB, Wysham C, Fisher M, Chevalier S, Cali AMG, Leroy B, Riddle MC. Bolli GB, et al. Among authors: cali amg. Diabetes Obes Metab. 2019 Feb;21(2):402-407. doi: 10.1111/dom.13515. Epub 2018 Oct 2. Diabetes Obes Metab. 2019. PMID: 30160030 Free PMC article.
The Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) study in type 2 diabetes: Achieving HbA1c targets with basal insulin in a real-world setting.
Meneghini LF, Mauricio D, Orsi E, Lalic NM, Cali AMG, Westerbacka J, Stella P, Candelas Dea C, Pilorget V, Perfetti R, Khunti K; DUNE investigators. Meneghini LF, et al. Among authors: cali amg. Diabetes Obes Metab. 2019 Jun;21(6):1429-1436. doi: 10.1111/dom.13673. Epub 2019 Mar 28. Diabetes Obes Metab. 2019. PMID: 30768845 Free PMC article.
Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus.
Freemantle N, Mauricio D, Giaccari A, Bailey T, Roussel R, Franco D, Berthou B, Pilorget V, Westerbacka J, Bosnyak Z, Bonnemaire M, Cali AMG, Nguyên-Pascal ML, Penfornis A, Perez-Maraver M, Seufert J, Sullivan SD, Wilding J, Wysham C, Davies M. Freemantle N, et al. Among authors: cali amg. Curr Med Res Opin. 2020 Apr;36(4):571-581. doi: 10.1080/03007995.2019.1708287. Epub 2020 Jan 19. Curr Med Res Opin. 2020. PMID: 31865758 Free article. Clinical Trial.
More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial.
Rosenstock J, Cheng A, Ritzel R, Bosnyak Z, Devisme C, Cali AMG, Sieber J, Stella P, Wang X, Frías JP, Roussel R, Bolli GB. Rosenstock J, et al. Among authors: cali amg. Diabetes Care. 2018 Oct;41(10):2147-2154. doi: 10.2337/dc18-0559. Epub 2018 Aug 13. Diabetes Care. 2018. PMID: 30104294 Clinical Trial.
Treatment Dosing Patterns and Clinical Outcomes for Patients with Type 2 Diabetes Starting or Switching to Treatment with Insulin Glargine (300 Units per Milliliter) in a Real-World Setting: A Retrospective Observational Study.
Gupta S, Wang H, Skolnik N, Tong L, Liebert RM, Lee LK, Stella P, Cali A, Preblick R. Gupta S, et al. Adv Ther. 2018 Jan;35(1):43-55. doi: 10.1007/s12325-017-0651-3. Epub 2018 Jan 8. Adv Ther. 2018. PMID: 29313285 Free PMC article.
45 results